Rebecca Lehto, PhD, RN, OCN, discusses patient use of complementary modalities during treatment for advanced lung cancer.
Rebecca Lehto, PhD, RN, OCN, assistant professor, College of Nursing, Michigan State University, discusses patient use of complementary modalities during treatment for advanced lung cancer.
Perioperative Tislelizumab Plus Chemo Improves Event-Free Survival in Resectable NSCLC
March 1st 2024Treatment with neoadjuvant tislelizumab plus platinum-based doublet chemotherapy, followed by surgery and adjuvant tislelizumab, improved event-free survival in patients with resectable non–small cell lung cancer.